Skip to main content

Qelbree News

Supernus Announces FDA Approval of Qelbree for the Treatment of ADHD in Adults

First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) – Supernus...

FDA Approves Qelbree (viloxazine) for the Treatment of ADHD

ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Attention-Deficit Hyperactivity Disorder (ADHD)

Qelbree patient information at Drugs.com